GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Acerus Pharmaceuticals Corp (TSX:ASP) » Definitions » Cyclically Adjusted PB Ratio

Acerus Pharmaceuticals (TSX:ASP) Cyclically Adjusted PB Ratio : 0.03 (As of Sep. 21, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Acerus Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2024-09-21), Acerus Pharmaceuticals's current share price is C$0.36. Acerus Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2022 was C$10.44. Acerus Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 0.03.

The historical rank and industry rank for Acerus Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

TSX:ASP's Cyclically Adjusted PB Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.77
* Ranked among companies with meaningful Cyclically Adjusted PB Ratio only.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Acerus Pharmaceuticals's adjusted book value per share data for the three months ended in Sep. 2022 was C$-2.405. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is C$10.44 for the trailing ten years ended in Sep. 2022.

Shiller PE for Stocks: The True Measure of Stock Valuation


Acerus Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Acerus Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acerus Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Acerus Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 0.48 0.45

Acerus Pharmaceuticals Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.54 0.45 0.85 0.27 0.18

Competitive Comparison of Acerus Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Acerus Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acerus Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Acerus Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Acerus Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Acerus Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Acerus Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.36/10.44
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Acerus Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2022 is calculated as:

For example, Acerus Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Sep. 2022 was:

Adj_Book=Book Value per Share/CPI of Sep. 2022 (Change)*Current CPI (Sep. 2022)
=-2.405/120.6479*120.6479
=-2.405

Current CPI (Sep. 2022) = 120.6479.

Acerus Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201212 9.027 95.760 11.373
201303 -6.543 97.103 -8.130
201306 34.173 97.182 42.425
201309 30.165 97.419 37.358
201312 16.974 96.945 21.124
201403 22.232 98.604 27.202
201406 15.513 99.473 18.815
201409 25.461 99.394 30.905
201412 16.473 98.367 20.204
201503 11.971 99.789 14.473
201506 11.207 100.500 13.454
201509 8.706 100.421 10.460
201512 -2.926 99.947 -3.532
201603 7.210 101.054 8.608
201606 15.466 102.002 18.293
201609 14.387 101.765 17.057
201612 21.171 101.449 25.178
201703 11.576 102.634 13.608
201706 10.476 103.029 12.268
201709 8.950 103.345 10.449
201712 14.296 103.345 16.690
201803 10.016 105.004 11.508
201806 7.305 105.557 8.349
201809 4.600 105.636 5.254
201812 -0.070 105.399 -0.080
201903 -0.973 106.979 -1.097
201906 -3.781 107.690 -4.236
201909 -7.783 107.611 -8.726
201912 -11.275 107.769 -12.622
202003 2.958 107.927 3.307
202006 1.607 108.401 1.789
202009 0.006 108.164 0.007
202012 0.527 108.559 0.586
202103 -1.533 110.298 -1.677
202106 -2.375 111.720 -2.565
202109 -3.067 112.905 -3.277
202112 -4.331 113.774 -4.593
202203 -0.757 117.646 -0.776
202206 -1.945 120.806 -1.942
202209 -2.405 120.648 -2.405

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Acerus Pharmaceuticals  (TSX:ASP) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Acerus Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Acerus Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Acerus Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
7025 Langer Drive, Suite 205, Mississauga, ON, CAN, L5N 0E8
Acerus Pharmaceuticals Corp is a specialty pharmaceutical company focused on the development, manufacture, marketing and distribution of branded products that improve patient experience, with a primary focus on the field of men's health. Its foundational product includes NATESTO, a testosterone therapy based on nasal gel technology. The company commercializes its products via its salesforce in the United States and Canada, and through a global network of licensed distributors in other territories.
Executives
Norma Beauchamp Director
Stephen Robert Gregory Director
Edward Joseph Gudaitis Director, Senior Officer

Acerus Pharmaceuticals Headlines